INKT Files 8-K Furnishing Q2 2025 Earnings Press Release

Rhea-AI Filing Summary

MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025 and furnished a related press release as Exhibit 99.1 to this Current Report on Form 8-K. The filing states that the information under Item 2.02 and Exhibit 99.1 is being furnished and therefore is not intended to be deemed filed for purposes of Section 18 of the Exchange Act. The 8-K itself does not include the underlying financial figures; the press release referenced in Exhibit 99.1 contains the detailed results and the Cover Page Interactive Data File is included as Exhibit 104.

Positive

• Press release furnished as Exhibit 99.1, indicating timely public disclosure of quarterly results
• Inline XBRL cover page (Exhibit 104) included, supporting data tagging and accessibility

Negative

• No financial figures are provided in the 8-K text itself; readers must consult Exhibit 99.1 for the results
• Furnished, not filed status limits Section 18 liability and may affect legal recourse regarding the disclosed information

Insights

Securities Analyst

TL;DR: The company publicly disclosed quarterly results via a furnished press release; the 8-K contains no financial detail itself.

The filing formally notifies investors that MiNK Therapeutics announced results for the quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1. The disclosure explicitly states the press release is furnished, not filed, limiting Section 18 liabilities. Because the 8-K does not include numeric financial data, material assessment relies on the content of Exhibit 99.1 rather than this form alone.

Corporate Governance Expert

TL;DR: Formally furnishing a press release is a routine disclosure step; the 8-K itself contains no new financial metrics.

From a governance and disclosure perspective, the company followed standard procedures by furnishing its earnings press release and including Inline XBRL cover page data. The filing clarifies the legal status of the furnished materials. The form does not present balance sheet, income statement, or MD&A text, so the governance implications are limited to timely public disclosure practice rather than substantive financial change.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

False000184022900018402292025-08-142025-08-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 14, 2025

_______________________________

MiNK Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-40908	82-2142067
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

149 Fifth Avenue, Suite 500

New York, New York 10010

(Address of Principal Executive Offices) (Zip Code)

(212) 994-8250

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.00001 par value per share	INKT	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2025, MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025. In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit 99.1 to this current report on Form 8-K.

The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibit

The following exhibit is furnished herewith:

99.1		Press Release dated August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MiNK Therapeutics, Inc.
Date: August 14, 2025	By:	/s/ Christine M. Klaskin
		Christine M. Klaskin
		Principal Financial Officer

FAQ

What did MiNK Therapeutics (INKT) disclose in this 8-K?

The company announced its financial results for the quarter ended June 30, 2025 and furnished a related press release as Exhibit 99.1 to the Form 8-K.

Are the financial results included directly in the 8-K?

No. The 8-K states the company announced results but does not include the underlying financial figures; those are furnished in the press release (Exhibit 99.1).

Is the press release considered filed or furnished?

The filing explicitly says the information under Item 2.02 and Exhibit 99.1 is furnished and therefore not intended to be filed for purposes of Section 18 of the Exchange Act.

Where can I find the detailed earnings information referenced in the 8-K?

The detailed results are contained in the press release attached as Exhibit 99.1 to the Form 8-K.

Who signed the Form 8-K for MiNK Therapeutics?

The Form 8-K was signed by Christine M. Klaskin, Principal Financial Officer.